Skip to content

HDS01 in improving gut health and wellbeing in healthy individuals.

Clinical validation of HDS01 in improving gut health and wellbeing in healthy individuals. - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/01/039308
Enrollment
30
Registered
2022-01-10
Start date
Unknown
Completion date
Unknown
Last updated
2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Naturedge Beverages Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Male and female subjects aged 18 to 60 years (both the ages inclusive) Ready to provide written informed consent Willing to come for the follow-up visits for evaluation With or without comorbidity and according to investigator discretion.

Exclusion criteria

Exclusion criteria: Presence of clinically significant known abnormal laboratory, ECG or X-ray findings during screening. Patients with known uncontrolled diabetes mellitus (DM) HbA1C more than 7.5, hypertension (HT), symptomatic congestive heart failure (CHF), unstable angina pectoris, myocardial infarction (MI) Subjects with current medical history of any major illness such as cancer, heart disease, COPD, Asthma etc. in the past Patients participated in another clinical drug trial within 3 months before recruitment in this trial Any other medical condition that in the Investigators opinion would preclude patient participation Pregnant and breast feeding women and women of child bearing age refusing to use contraceptive measures Immunologically compromised individuals Subjects with past history of addiction abuse and rehabilitation Subject consuming more than 1 cigarette per day

Design outcomes

Primary

MeasureTime frame
1.Changes in Quality of life of subjects by GHQ-29 questionnaire 2.Changes in digestive complaints (Bloating, Heartburn, Flatulence, Constipation, Post Prandial Fullness etc.) in subjects 3.Changes in digestive behavior questionnaire (Gut health) 4.Changes in energy audit questionnaire scoreTimepoint: Screening, Baseline, Day 30

Secondary

MeasureTime frame
1.Changes in Liver function parameters 2.Tolerability of intervention by study subjectsTimepoint: Screening, Baseline, Day 30

Countries

India

Contacts

Public ContactMr Sharad Dhurde

Naturedge Beverages Pvt. Ltd.

bshrikhande@siddhayu.com9371490526

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026